Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai’s Lenvima Will Face Off Against Nexavar In Thyroid Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Approved two months early, tyrosine kinase inhibitor’s labeling reflects 14.7-month progression-free survival improvement in patients with differentiated thyroid cancer, almost triple the benefit seen with Bayer/Amgen’s sorafenib.


Related Content

Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't
Keeping Track: Submissions Galore, And Still More 'Breakthroughs'
Eisai’s Lenvima Gets CHMP Backing, Nexavar Marketing Rivalry Looms
AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key
Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts